Farzane Vafaei

Farzane Vafaei

Auto-generated profile, based on publicly available information

Farzane Vafaei

Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Isfahan, Iran

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in BioMed Research International
Verified
Journal Article
Open access
PDF file
TTTahere Tabatabaei
Tahere Tabatabaei
MRMohammad Reza Rezvany
Mohammad Reza Rezvany
BGBahare Ghasemi
Bahare Ghasemi
FVFarzane Vafaei
Farzane Vafaei
MZMasoumeh Kiani Zadeh
Masoumeh Kiani Zadeh
ASArash Salmaninejad
Arash Salmaninejad
Epigenetic alterations have been observed in many hematological malignancies, including acute myeloid leukemia (AML). Many of these alterations result from mutations in DNA methyl transferase (DNMT) enzymes, disabling them to methylate target genes in a proper way. In this case-control study, we investigated the association between R882H mutation in DNMT3A gene and DDX43 gene methylation in patients with AML. 47 AML patients and 6 controls were included in this study. After DNA extraction, amplification refractory mutation system (ARMS)-PCR was used to evaluate R882H mutations in DNMT3A gene. The high-resolution melting (HRM) method was used to determine the methylation changes of the DDX43 gene promoter. R882H mutation was only found in 10.6% (5 out of 47) of AML patients. The frequency of DDX43 gene methylation was significantly higher in patients without R882H mutations compared to patients with R882H mutations (P<0.05). The DNMT3A R882H mutation is typically present in a minority of AML patients. Nevertheless, this mutation is associated with a reduced frequency of methylation in the DDX43 promoter region.